PIAZZA ROCCO GIOVANNI

Ruolo:

Professore associato

Settore scientifico disciplinare:

MALATTIE DEL SANGUE (MED/15)

Afferenza:

E-mail:

Telefono:

0264488059
0264488015

Stanza:

U08, Piano: P04, Stanza: 4043
Via Cadore, 48 - 20900 MONZA

U8, Piano: IV, Stanza: LABORATORIO 4.10
Via Cadore, 48 - 20900 MONZA

Ramazzotti, D., Angaroni, F., Maspero, D., Ascolani, G., Castiglioni, I., Piazza, R., et al. (2020). Longitudinal cancer evolution from single cells [Rapporto tecnico]. Dettaglio
Magistroni, V., Mauri, M., D'Aliberti, D., Mezzatesta, C., Crespiatico, I., Nava, M., et al. (2019). De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. HAEMATOLOGICA, 104(9), 1789-1797. Dettaglio
Angaroni, F., Graudenzi, A., Rossignolo, M., Maspero, D., Calarco, T., Piazza, R., et al. (2019). Personalized therapy design for liquid tumors via optimal control theory [Altro]. Dettaglio
Crespiatico, I., Bossi, E., Brioschi, F., Piazza, R., Mologni, L., & Gambacorti‐passerini, C. (2019). An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization. CLINICAL CASE REPORTS. Dettaglio
Sharma, G., Cortinovis, D., Agustoni, F., Arosio, G., Villa, M., Cordani, N., et al. (2019). A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. JOURNAL OF THORACIC ONCOLOGY, 14(11), e257-e259. Dettaglio

Futuri studenti